Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 1;4(1):129-136.
doi: 10.1159/000539922. eCollection 2024 Jan-Dec.

Rituximab in Steroid-Dependent Podocytopathies

Cláudia Costa  1 , Amélia Antunes  2 , João Oliveira  1 , Marta Pereira  1 , Iolanda Godinho  1 , Paulo Fernandes  1 , Sofia Jorge  1 , José António Lopes  1   2 , Joana Gameiro  1   2
Affiliations

Rituximab in Steroid-Dependent Podocytopathies

Cláudia Costa et al. Glomerular Dis. .

Abstract

Introduction: Rituximab (RTX) has been reported as an effective treatment alternative in primary forms of minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS) associated with steroid dependence and frequent relapses. However, the optimal RTX regimen and the outcomes of further doses of RTX remain unclear. This study aimed to evaluate the use of induction and maintenance RTX therapy for adults with primary podocytopathies.

Methods: We performed a retrospective case series on adult patients with steroid-dependent podocytopathies who received an induction RTX therapy. Maintenance therapy was performed at physician's discretion. Remission and relapse rates, concomitant corticosteroids and immunosuppressants use, B-cell depletion and adverse events were analyzed.

Results: Fourteen patients (mean age at start of RTX 29.1 ± 21.9 years) with MCD (n = 7) or FSGS (n = 7) were treated with 2 doses of 1,000 mg 2 weeks apart (n = 13) or four doses of 375 mg/m2 (n = 1) of RTX. At last follow-up (mean 47.3 ± 101.7 months), 10 patients were in complete remission and two remained in partial remission. A reduction in the number of relapses, number of patients under corticosteroids and immunosuppressants, and dose of prednisolone was observed when compared to baseline (14 [100%] vs. 5 [35.7%]; 8/14 [57.1%] vs. 4/12 [33.3%]; 13/14 [92.9%] vs. 7/12 [58.3%]; 20 mg/day vs. 5.25 mg/day, respectively). Maintenance RTX therapy was used in 6 patients, with sustained complete remission. Infusion reactions were observed in 4 patients (one required treatment withdrawal).

Conclusions: Our findings support the use of RTX for a steroid-free remission in podocytopathies and suggest that maintenance RTX is well-tolerated and associated with prolonged remission. Further studies are needed to confirm its efficacy and safety and establish the optimal induction and maintenance RTX regimen in steroid-dependent podocytopathies.

Keywords: Focal and segmental glomerulosclerosis; Minimal change disease; Nephrotic syndrome; Podocitopathies; Rituximab.

Plain language summary

Rituximab (RTX) seems to be an effective treatment alternative in primary forms of MCD and FSGS, particularly in cases of steroid dependence and frequent relapses. Our findings support the use of RTX for a steroid-free remission in podocytopathies and suggest that maintenance RTX is well-tolerated and associated with prolonged remission. Further studies are needed to confirm its efficacy and safety and establish the optimal induction and maintenance RTX regimen in steroid-dependent podocytopathies.

PubMed Disclaimer

Conflict of interest statement

There is no conflict of interest. The results presented in this paper have not been published previously in whole or part.

Similar articles

See all similar articles

References

    1. Maas RJ, Deegens JK, Smeets B, Moeller MJ, Wetzels JF. Minimal change disease and idiopathic FSGS: manifestations of the same disease. Nat Rev Nephrol. 2016;12(12):768–76. - PubMed
    1. Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, et al. . Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol. 2022;33(1):238–52. - PMC - PubMed
    1. Nimkar A, Yang Y, Jhaveri KD. Rituximab with tacrolimus for relapsing diffuse podocytopathy in adulthood: a therapeutic option. Clin Nephrol. 2023;100(2):95–8. - PubMed
    1. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. . Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases. Kidney Int. 2021;100(4):753–79. - PubMed
    1. Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, et al. . Rituximab in adult minimal change disease and focal segmental glomerulosclerosis: what is known and what is still unknown? Autoimmun Rev. 2020;19(11):102671. - PubMed

LinkOut - more resources